In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma

Haematologica June 2018 : haematol.2018.189241; doi:10.3324/haematol.2018.189241

Overall, our results show that the QTX125 compound obtained is a new HDAC6-specific inhibitor that causes cell-growth inhibition and programmed cell death in association with increased levels of acetylated α-tubulin, its most recognizable target. The antitumoral effect is particularly evident in MCL models, both in culture and in vivo, surpassing the efficacy of currently available HDAC6 inhibitors. Thus, QTX125 constitutes a novel candidate agent whose utility in epigenetic lymphoma therapy warrants further assessment, its efficacy in the preclinical setting having been demonstrated herein.



   Paseo Mikeletegi 69, 3ª planta

   20009 San Sebastián

   Tel: 946 08 70 37